Myomo, Inc. reported a 21% increase in revenue to $1.0 million for the first quarter of 2020, driven by a higher average selling price from record direct billing revenues. The authorization backlog also increased by 51% sequentially. However, the company anticipates a substantial decrease in revenue for the second quarter due to public health mandates and travel restrictions.
Revenue increased by 21% year-over-year to $1.0 million.
Direct billing accounted for a record 62% of total revenue.
Gross margin increased by 300 basis points to 68.4%.
Authorization backlog increased by 51% to 80 units.
Myomo anticipates that second quarter revenue will be substantially below first quarter revenue due to public health mandates and travel restrictions. They have taken actions to reduce costs by over $500,000 in the second quarter and are hopeful that operations will return to a more normal pace in the coming weeks. The authorization backlog currently stands at a record 100 MyoPro units.